close

Ewa M. Davison, Ph.D.

Associate, Litigation  

Seattle 206.389.4564

Overview

Ewa Davison, Ph.D., focuses her practice on litigating patent matters for companies in the life sciences, biotechnology, pharmaceutical and chemistry arenas. Ewa’s experience includes resolving disputes in the federal district courts and the Court of Appeals for the Federal Circuit, in addition to her growing inter partes review (IPR) practice.

Ewa was selected as a Washington “Rising Star” in the area of Intellectual Property Litigation in 2016 and 2015, and recently completed a trial fellowship with the King County Prosecutor’s Office. She served as a managing editor of the Washington Law Review while in law school. At MIT, she worked in the laboratory of Dr. H. Robert Horvitz, winner of the 2002 Nobel Prize in Physiology or Medicine. Ewa was awarded several academic distinctions while an undergraduate at Princeton University.

Prior to joining Fenwick & West, Ewa clerked for the Honorable Richard C. Tallman of the Ninth Circuit Court of Appeals.

Legal Publications

  • Armen N. Nercessian and Ewa M. Davison, Litigation Alert: Supreme Court Extends Petrella Rule Barring Laches to Patent Context, March 2017.
  • Ewa M. Davison and Amy E. Hayden, Biosimilars: Solicitor General Recommends Granting Certiorari in Amgen v. Sandoz, Life Sciences Legal Insights Blog, December 2016.
  • Amy E. Hayden and Ewa M. Davison, Will the Supreme Court Review Whether FDA-Mandated Bioequivalence Testing to Maintain Approval Falls Within the § 271(e)(1) Safe Harbor?, Life Sciences Legal Insights Blog, August 2016.
  • Amy E. Hayden, Ewa M. Davison and David Tellekson, Federal Circuit: A Biosimilar Applicant Must Provide Notice of Intent to Market a Biosimilar Product, No Exceptions, Life Sciences Legal Insights Blog, July 2016.
  • Amy E. Hayden, Ewa M. Davison, and David K. Tellekson, Litigation Alert: No Exception to Statutory Requirement that a Biosimilar Applicant Provide Notice of Intent to Market its Product, July 2016.
  • Adam Lewin and Ewa M. Davison, Federal Circuit clarifies the 'on-sale bar.' (The Medicines Co. v. Hospira, Inc.), The Los Angeles Daily Journal, July 2016.
  • Amy E. Hayden, Ewa M. Davison and David K. Tellekson, The Amgen Quagmire: Federal Circuit Rules Patent Dance Does Not Excuse Biosimilar Applicants from Providing Notice of Intent to Market, IPWatchdog, July 2016.
  • Jeffrey Ware, Ewa M. Davison and David K. Tellekson, Supreme Court Refuses to Put the Brakes on PTAB, The Recorder, June 2016.
  • Amy E. Hayden, Ewa M. Davison and David K. Tellekson, Biosimilars: Supreme Court Calls for Solicitor General’s vVews in Amgen v. Sandoz, June 2016.
  • Jeffrey Ware, Ewa M. Davison, and David Tellekson, Litigation Alert: Supreme Court Leaves Intact PTAB Authority to Institute and Regulate Inter Partes Review Proceedings, June 2016.
  • Adam Lewin, Ewa M. Davison and Bryan Kohm, Biotech companies turn to ITC forum. (International Trade Commission), The Los Angeles Daily Journal, April 2016.
  • Ewa M. Davison and David Tellekson, Riddle Me This: The Federal Circuit Provides a Measure of Clarity to the Enigmatic Biosimilar Approval Pathway, August 11, 2015.
  • Ewa M. Davison and David K. Tellekson, Murky Waters: Post-Approval Regulatory Activities and the § 271(e)(1) Safe Harbor, Intellectual Property Bulletin, Winter 2013.
  • Ewa M. Davison, Melanie L. Mayer and Stuart P. Meyer, Final Patent Rules Provide Few Surprises, Intellectual Property Bulletin, Summer 2012.
  • Stuart P. Meyer, Ewa M. Davison and Melanie L. Mayer, IP Litigation Alert: PTO Publishes Final Rules for Contested Patent Cases, August 2012.
  • David K. Tellekson and Ewa M. Davison, Litigation Alert: Supreme Court Leaves Intact PTAB Authority To Institute And Regulate Inter Partes Review Proceedings, June 2012.
  • David K. Tellekson and Ewa M. Davison, Supreme Court Allows Generic Manufacturers To Challenge Overbroad Use Codes, Intellectual Property Bulletin, Spring 2012.
  • Heather N. Mewes, David Tellekson and Ewa M. Davison, Patent Litigation Alert: Supreme Court Allows Generic Manufacturers to Challenge Overbroad Use Codes, April 2012.
  • Ewa M. Davison and David K. Tellekson, California Supreme Court to Hear Cipro “Pay-for-Delay” Case, February 2012.
  • Steve P. Calandrillo and Ewa M. Davison, The Dangers of the Digital Millennium Copyright Act: Much Ado About Nothing?, 50 Wm. & Mary L. Rev. 349 (2008).
  • Ewa M. Davison & Gary M. Myles, How Biotech Patentees Can Navigate KSR, Managing Intellectual Property, July/August 2008, at 79.
  • Ewa M. Davison, Enjoys Long Walks on the Beach: Washington’s Public Trust Doctrine and the Right of Pedestrian Passage over Private Tidelands, 81 Wash. L. Rev. 813 (2006).​

Scientific Publications

  • Davison, E.M., Saffer, A.M., Huang, L.S., DeModena, J., Sternberg, P.W., and Horvitz, H.R. (2011). The LIN-15A and LIN-56 Transcriptional Regulators Interact to Negatively Regulate EGF/Ras Signaling in Caenorhabditis elegans Vulval Cell-Fate Determination. Genetics 187, 803-815.
  • Davison, E.M., Harrison, M.M., Walhout, A.J.M., Vidal, M., and Horvitz, H.R. (2005). lin-8, which antagonizes C. elegans Ras-mediated vulval induction, encodes a novel nuclear protein that interacts with the LIN-35 Rb protein. Genetics 171, 1017–1031.
  • Bollag, R.J., Siegfried, Z., Cebra-Thomas, J.A., Garvey, N., Davison, E.M., and Silver, L.M. (1994). An ancient family of embryonically expressed mouse genes sharing a conserved protein motif with the T locus. Nature Genetics 7, 383–389.

Legal Presentations

  • Patent Law Year in Review CLE, Fenwick & West, 2014 – 2016.
  • BIO IPCC Spring 2017, “Toto, I’ve a Feeling We’re Not in Texas Anymore . . .” (Panel Presentation).
  • BIO IPCC Spring 2016, “Evolution or Devolution? Developments at the PTAB” (Patent Presentation).